The US Food and Drug Administration beats the European Medicines Agency to approval of novel agents across the board, but the imbalance is even more stark in oncology, the largest therapy area, a Pink Sheet analysis found.
European approval preceded the FDA’s assent for only one of the 22 cancer therapeutics approved in the US or the...








